(Q28085359)

English

Rescue Therapy with a Proton Pump Inhibitor Plus Amoxicillin and Rifabutin for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis

scientific article

In more languages

Statements

scholarly article

1 reference

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

Europe PubMed Central

Rescue Therapy with a Proton Pump Inhibitor Plus Amoxicillin and Rifabutin for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis (English)

1 reference

Helicobacter pylori

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Helicobacter pylori infectious disease

1 reference

based on heuristic

inferred from title

author name string

Xiaoqun Liu

1

1 reference

Hui Wang

2

1 reference

Zhifa Lv

3

1 reference

Youhua Wang

4

1 reference

Ben Wang

5

1 reference

Yong Xie

6

1 reference

Xiaojiang Zhou

7

1 reference

Nonghua Lv

8

1 reference

language of work or name

1 reference

publication date

2015

1 reference

Gastroenterology research and practice

1 reference

2015

1 reference

415648

1 reference

copyright license

Creative Commons Attribution 3.0 Unported

1 January 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

20 March 2017

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

20 March 2017

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

20 March 2017

Antimicrobial susceptibility of Helicobacter pylori isolates from Lower Silesia, Poland

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

Practical treatment of Helicobacter pylori: a balanced view in changing times

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

Evidence-based recommendations for successful Helicobacter pylori treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

Diagnosis and epidemiology of Helicobacter pylori infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

Rifabutin-associated hypopyon uveitis and retinal vasculitis with a history of acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

Review article: rifabutin in the treatment of refractory Helicobacter pylori infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

Worldwide H. pylori antibiotic resistance: a systematic review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

American College of Gastroenterology guideline on the management of Helicobacter pylori infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

'Rescue' therapies for the management of Helicobacter pylori infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

Methodological index for non-randomized studies (minors): development and validation of a new instrument

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

In vitro activity of clarithromycin against intracellular Helicobacter pylori.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

29 September 2017

Safety of rifabutin replacing rifampicin in the treatment of tuberculosis: a single-centre retrospective cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

2 June 2018

Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

2 June 2018

Helicobacter pylori infection and the development of gastric cancer.

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F415648

21 January 2018

Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F415648

21 January 2018

Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F415648

21 January 2018

Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F415648

21 January 2018

Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F415648

21 January 2018

Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F415648

21 January 2018

Empirical Helicobacter pylori "rescue" therapy after failure of two eradication treatments

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F415648

21 January 2018

Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F415648

21 January 2018

Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F415648

21 January 2018

Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience.

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F415648

21 January 2018

The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F415648

21 January 2018

Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F415648

21 January 2018

One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F415648

21 January 2018

[Comparison of rifabutin- and levofloxacin-based third-line rescue therapies for Helicobacter pylori].

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F415648

21 January 2018

Severe neutropenia among healthy volunteers given rifabutin in clinical trials

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F415648

21 January 2018

Rifabutin-associated uveitis in an immunocompetent individual with Mycobacterium simiae

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F415648

21 January 2018

Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

27 November 2018

[An update on the antibiotic therapy of tuberculosis]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4461753

27 November 2018

Helicobacter pylori: usefulness of an empirical fourth-line rifabutin-based regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/26106411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments

1 reference

https://pubmed.ncbi.nlm.nih.gov/26106411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current European concepts in the management of Helicobacter pylori infection - the Maastricht Consensus Report

1 reference

https://pubmed.ncbi.nlm.nih.gov/26106411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Severe neutropenia caused by recommended prophylactic doses of rifabutin

1 reference

https://pubmed.ncbi.nlm.nih.gov/26106411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Cross-resistance between rifampin and rifabutin in multidrug resistant Mycobacterium tuberculosis complex strains]

1 reference

https://pubmed.ncbi.nlm.nih.gov/26106411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/26106411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Rifabutin-associated bilateral uveitis: a case report]

1 reference

https://pubmed.ncbi.nlm.nih.gov/26106411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures

1 reference

https://pubmed.ncbi.nlm.nih.gov/26106411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1155/2015/415648

1 reference

1 reference

1 reference

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28085359&oldid=1808493791"